gastroenterology

Pharmacists on the Front Line in Constipation Treatment
Pharmacists on the Front Line in Constipation TreatmentConstipation is a common problem, but can stem from a variety of sources. Here's how pharmacists can help.
How Hospice Pharmacists Deal with Constipation
How Hospice Pharmacists Deal with Constipation
Game changing idea: Specialty intensive medical homeBlue Cross Blue Shield of Illinois partners with gastroenterology group to focus on Crohn’s disease patients.
Study: Genetic variants determine whether aspirin/NSAIDS will reduce colorectal cancer riskRegular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) appears to reduce the risk of colorectal cancer in most individuals, but a few individuals with rare genetic variants do not share this benefit, according to a study published in the March 17 issue of JAMA.
Concurrent famotidine reduces ibuprofen-related ulcers (VIDEO)William Fredette, MD, disccuses a study published in the American Journal of Gastroenterology, which reports that chronic NSAID users develop fewer ulcers if they take ibuprofen plus high-dose famotidine rather than ibuprofen alone. Video provided by The Doctor's Channel.
Pathophysiology of Gastroesophageal Reflux Disease (GERD) (VIDEO)Chait Maxwell, MD, Gastroenterologist with the ColumbiaDoctors Medical Group, discusses Gastroesophageal Reflux Disease (GERD), one of the most common upper GI maladies affecting people in the United States. Video provided by The Doctor's Channel.
New oral anticoagulants increase risk for GI bleeding: StudyPatients taking the new generation of oral anticoagulants (nOACs) are associated with a significantly higher risk of gastrointestinal bleeding (GIB), according to a new study.
Colonoscopy remains high value preventive carePlan's data show 1.2% of screenings resulted in cancer diagnosis
Actavis to buy Warner Chilcott for $8.5 billion in stock transactionActavis Inc. announced May 20 its plans to acquire Warner Chilcott in a stock transaction deal, which is worth approximately $8.5 billion. The merger is expected to create a global specialty pharmaceutical company serving the women’s health, gastroenterology, urology, and dermatology therapeutic sectors, according to a joint company release.